Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023

ConclusionsInterim results from six European studies during the 2022/23 influenza season indicate a ≥ 27% and ≥ 50% reduction in disease occurrence among all-age influenza vaccine recipients for influenza A and B, respectively, with higher reductions among children. Genetic virus characterisation results and end-of-season VE estimates will contribute to greater understanding of differences in influenza (sub)type-specific results across studies.

Source: Eurosurveillance - May 25, 2023 Category: Infectious Diseases Authors: Esther Kissling, Marine Maurel, Hanne-Dorthe Emborg, Heather Whitaker, Jim McMenamin, Jennifer Howard, Ramona Trebbien, Conall Watson, Beth Findlay, Francisco Pozo, Amanda Bolt Botnen, Ciaran Harvey, Angela Rose and European IVE group Source Type: research